TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of delirium during the first 3 days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Postoperative Cognitive Dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chronic postsurgical pain (CPSP) at 3 months after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants to receive the full initial, weight-based dose of enzyme replacement therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with improvement or resolution of hydrops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer event-free survival (BC-EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Pre-morbid functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of new atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ambiguity tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Letter fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal and spatial parameters of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of at Least One Major Complication related to Breast Reconstruction After Stage 1
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in BREAST-Q Satisfaction with Breasts Score from Pre-Mastectomy After Stage 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility measured through recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility measured through retention in sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility measured through retention in follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to awakening after drug injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modena Bleeding Score (MBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of postpartum visits attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in arterial most diseased segment (MDS) 18-FDG-PET target-to-background ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of fluoropyrimidine induced cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients alive without liver transplant
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic pain endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of iberdomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of COVID-19 testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of vaccinations - Pfizer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of vaccinations - Moderna
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of vaccinations - Johnson and Johnson
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Doses of vaccine received - Pfizer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Doses of vaccine received - Moderna
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Doses of vaccine received - Johnson and Johnson
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uptake of Genetic Counseling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uptake of Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of occurrences of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic (PK) plasma concentration of BnH-015B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriateness of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Relative change in Proteinuria value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Efficacy of the CASPER algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of HPB-releasing adducts (buccal cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Disability Assessment Scale (DAS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Analyte concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairing effects of cannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological activity of human-enriched serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the live attenuated varicella vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Center of mass velocity and acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validated abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HBA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in respiratory quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance on the Belief Updating Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on the Affective Picture Paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with complete cytoreduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Well-baby care engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Timely vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with laboratory analyte results above upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with vital sign results considered clinically significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to outpatient procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Salivary Opiorphin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in respiratory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bland-Altman method accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to ISO criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CLSI-POCT criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surveillance Error Grid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clarke Error Grid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with successful reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sarcopenia Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Success of the Left Atrial Posterior Wall Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Success of the Mitral Isthmus Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Ocular Surface Disease Index scores to the First Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Surface Disease Index scores to the Second Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itch Scale: Visual Analogue Scale Itch (VAS Itch)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Preparedness for Caregiving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Care partner satisfaction of care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of Knowledge and Awareness of Dry Needling Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: asthma-related hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of disability at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of both guides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of radiomics-derived parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Habit formation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Electrode set up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuromuscular performance (power production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuromuscular performance (1-repetition maximum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in MSQOL-54 Instrument scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum concentration (Cmax) of sulbactam and durlobactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to 24 hours (AUC 0-24) of sulbactam and durlobactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Worst Bladder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of natural salmon oil vs standard omega-3 supplement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oral Aperture measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Percent of subjects with complete (100%) occlusion of the target aneurysm and ≤50% stenosis of the parent artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants reporting dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Clinical complete response (cCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstruation Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Plaque Index (MPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspiration Skill Self-Assessment score average
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: General Self-Efficacy Belief Scale score average
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain reduction rate at 6 weeks postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rosacea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neuropsychiatric Inventory Questionnaire (NPI-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornell Scale for Depression in Dementia (CSDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized Anxiety Disorder-7 Scale (GAD-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with AEs leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence rate of priapism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of residual cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain, function, and overall well-being connected to musculoskeletal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Menstrual function and history & fertility function and history
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantitative ultrasound elastography score for pancreatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of recurrent or metastatic thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neonatal Comfort Behaviour Scale (NCCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AFib burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with POAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first recurrence of atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge and attitude score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HiSCR50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Glucose Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral Sucralose Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral MDG Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of complication detection
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion rates of HI antibody against all types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of adverse events/adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to HN2301
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and severity of AEs and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lateral flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thoracic extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular End-Diastolic Diameter (LVEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cervical Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum Melatonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in knee extensor fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in perceived fatigability
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of recruited participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of myocardial abnormalities identified by CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Avoidance learning measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity during avoidance learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HOPE 2.0 Program Adoption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HOPE 2.0 Implementation cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity of Implementing HOPE 2.0
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of all adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Score on Maternal Breastfeeding Evaluation Scale (MBFES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding Self-Efficacy Scale - Short Form (BSES-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuous physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily lung mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-reported patient symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composition of fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain 24 hours after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing adverse events (AEs)/serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Follow-up of individuals with suspected genetic predisposition to cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of AE and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: The recommended dose for expansion (RDE) and/or maximum tolerated dose (MTD) of CD-001 monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Number and/or Dosage of Antihypertensive Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of sexual health questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of depression questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of skin hydration scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraocular Pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Death Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of pulmonary hypertension or right ventricular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastric emptying of solids T1/2 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and intensity of solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and intensity of unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean concentration (GMC) and seroconversion rate of antigen-specific antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seasonal influenza vaccination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSMQ Glucose Management Domain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DSMQ Dietary Control Domain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DSMQ Physical Activity Domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning